hims - Search News

Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings to offset any impact from impending restrictions on selling copies of Novo Nordisk's obesity drug.

Quartz on MSN · 1h

Hims & Hers stock slipped as investors were left unimpressed with its new weight-loss drug options

Hims & Hers (HIMS) stock slid Wednesday, a day after the company announced new weight-loss drug offerings — an update that left investors unimpressed.

The Wall Street Journal on MSN · 10h

Hims & Hers Expands Weight Loss Offering, Adds Lilly’s Zepbound to Platform

The telehealth-consultation platform said it plans to continue expanding its weight loss offerings.

4hon MSN

Hims & Hers Zepbound Offering Won’t Bring Needed Sales Boom, Analysts Say

Investors worry patients won’t make that price leap and that Hims, which has built its business on affordable healthcare, ...

26mon MSN

Why Hims & Hers Health Stock Couldn't Beat the Market Today

Hims & Hers Health ( HIMS 0.37%) stock labored mightily on Wednesday, but in the end, it couldn't top the benchmark S&P 500 index. Investor excitement about news of a fresh product launch the previous ...

Modern Healthcare7h

Eli Lilly denies affiliation with Hims & Hers

Eli Lilly quickly disassociated itself from Hims & Hers after the telehealth company said it was selling the pharmaceutical ...

Where Will Hims & Hers Stock Be in Five Years? Here’s What This Top Investor Expects

Hims & Hers Health (NYSE:HIMS) has taken investors on a wild ride in 2025. The stock surged nearly 200% earlier this year, ...

Zepbound Now Available Through Hims & Hers

Zepbound is made by drugmaker Eli Lilly. While Hims & Hers offers it for $1,899 per month, Lilly said the price on its own LillyDirect platform starts at $349 for self-paying customers. With insurance ...